KRAS and cancer: Besides chemical inhibitors, new therapeutics targeting KRAS mutant cancers include exosome-delivered KRAS siRNA (iExosome), mRNA vaccines, anti-KRAS T cell transfer, and cell-permeable RAS antibodies [5].